Hepatocellular carcinoma screening and diagnosis

Area of Science:

• Hepatology
• Oncology
• Diagnostic Imaging

Background:

• Major liver disease societies recommend screening for hepatocellular carcinoma (HCC).
• Risk stratification for HCC screening includes patients with hepatitis B and those with cirrhosis.
• Current screening methods involve ultrasound, with additional biomarker use in Asia.

Purpose of the Study:

• To review current recommendations and practices for HCC screening.
• To discuss the role of risk scores, screening intervals, and diagnostic tools in HCC management.
• To evaluate the utility of biomarkers in conjunction with imaging for HCC detection.

Main Methods:

• Review of guidelines and literature on HCC screening protocols.
• Analysis of risk score development for specific patient populations.
• Discussion of imaging criteria and histopathological stains for HCC confirmation.

Main Results:

• Ultrasound is the primary screening tool, with an ideal interval of 6 months.
• Biomarker utility in addition to ultrasound has not been definitively proven.
• Radiological criteria and special stains aid in confirming HCC and differentiating lesions.

Conclusions:

• HCC screening is crucial for early detection and improved patient outcomes.
• A combination of risk assessment, appropriate screening intervals, and diagnostic tools is essential for effective HCC management.
• Further research is needed to validate the role of biomarkers in HCC screening.